| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Gene transfer by lentiviral vectors is limited by nuclear translocation and rescued by HIV-1 pol sequences.
|
Nat Genet
|
2000
|
6.12
|
|
2
|
International standardized approach for flow cytometric residual disease monitoring in chronic lymphocytic leukaemia.
|
Leukemia
|
2007
|
2.96
|
|
3
|
Survivin is expressed on CD40 stimulation and interfaces proliferation and apoptosis in B-cell chronic lymphocytic leukemia.
|
Blood
|
2001
|
1.79
|
|
4
|
Distribution of interferon-gamma receptor in human tissues.
|
Eur J Immunol
|
1992
|
1.30
|
|
5
|
Expression of beta 1B integrin isoform in CHO cells results in a dominant negative effect on cell adhesion and motility.
|
J Cell Biol
|
1994
|
1.24
|
|
6
|
A flow cytometry assay simultaneously detects independent apoptotic parameters.
|
Cytometry
|
2001
|
1.22
|
|
7
|
IL-12 inhibition of endothelial cell functions and angiogenesis depends on lymphocyte-endothelial cell cross-talk.
|
J Immunol
|
2001
|
1.10
|
|
8
|
Growth stimulation of colorectal carcinoma cells via the c-kit receptor is inhibited by TGF-beta 1.
|
J Cell Physiol
|
1997
|
1.08
|
|
9
|
CD38 molecule: structural and biochemical analysis on human T lymphocytes, thymocytes, and plasma cells.
|
J Immunol
|
1990
|
1.04
|
|
10
|
Chronic systemic high-dose recombinant interferon alfa-2a reduces exacerbation rate, MRI signs of disease activity, and lymphocyte interferon gamma production in relapsing-remitting multiple sclerosis.
|
Neurology
|
1994
|
1.03
|
|
11
|
Interferon alpha-2a treatment of relapsing-remitting multiple sclerosis: disease activity resumes after stopping treatment.
|
Neurology
|
1996
|
0.89
|
|
12
|
Analysis of the human CD36 leucocyte differentiation antigen by means of the monoclonal antibody NL07.
|
Cell Immunol
|
1991
|
0.88
|
|
13
|
Prolactin is an autocrine growth factor for the Jurkat human T-leukemic cell line.
|
J Neuroimmunol
|
1997
|
0.88
|
|
14
|
Identification of a new epitope of the 4F2/44D7 molecular complex present on sarcolemma and isolated cardiac fibers.
|
Eur J Immunol
|
1989
|
0.87
|
|
15
|
Regulatory action of prolactin on the in vitro growth of CD34+ve human hemopoietic progenitor cells.
|
J Cell Physiol
|
1995
|
0.87
|
|
16
|
Independent and synergistic effect of interleukin-2 and prolactin on development of T- and NK-derived LAK effectors.
|
Immunopharmacology
|
1994
|
0.87
|
|
17
|
MIB-1, Ki67, and PCNA scores and DNA flow cytometry in intermediate grade malignant lymphomas.
|
J Clin Pathol
|
1994
|
0.87
|
|
18
|
Expression of prolactin and prolactin receptors by non-Hodgkin's lymphoma cells.
|
Int J Cancer
|
2000
|
0.86
|
|
19
|
ZAP-70 is expressed by normal and malignant human B-cell subsets of different maturational stage.
|
Leukemia
|
2006
|
0.83
|
|
20
|
Prolactin increases the susceptibility of primary leukemia cells to NK and LAK effectors.
|
Adv Neuroimmunol
|
1996
|
0.83
|
|
21
|
Immunophenotype of thymoma-associated lymphoid cell component of T-cell type. A new analytic procedure in keeping with structural heterogeneities.
|
Virchows Arch B Cell Pathol Incl Mol Pathol
|
1990
|
0.82
|
|
22
|
Human CD38 and its ligand CD31 define a unique lamina propria T lymphocyte signaling pathway.
|
FASEB J
|
2001
|
0.82
|
|
23
|
Prolactin in autoimmunity and antitumor defence.
|
J Neuroimmunol
|
2000
|
0.82
|
|
24
|
Individual and combined effect of granulocyte-macrophage colony-stimulating factor and prolactin on maturation of dendritic cells from blood monocytes under serum-free conditions.
|
Immunology
|
2000
|
0.82
|
|
25
|
p53 evaluation in gastric mucosa of patients with chronic Helicobacter pylori infection.
|
Anticancer Res
|
2001
|
0.81
|
|
26
|
Interferon alpha treatment of relapsing-remitting multiple sclerosis: long-term study of the correlations between clinical and magnetic resonance imaging results and effects on the immune function.
|
Mult Scler
|
1995
|
0.81
|
|
27
|
Flow cytometry in breast cancer: prognostic and surgical indications of the sparing of axillary lymph node dissection.
|
Am J Clin Oncol
|
1998
|
0.80
|
|
28
|
DNA ploidy and p53 expression correlate with survival and cell proliferative activity in male breast carcinoma.
|
Hum Pathol
|
1996
|
0.79
|
|
29
|
In vitro and in vivo comparison of the activity of human lymphokine-activated killer (LAK) cells and adherent LAK cells.
|
J Immunother (1991)
|
1991
|
0.79
|
|
30
|
Long-term survival of thymoma patients by histologic pattern and proliferative activity.
|
Am J Surg Pathol
|
1995
|
0.78
|
|
31
|
Cytolytic and tumor inhibitory antibodies against UK114 protein in the sera of cancer patients.
|
Int J Oncol
|
1997
|
0.77
|
|
32
|
Modulation of extracellular matrix receptors (integrins) on human endothelial cells by cytokines.
|
EXS
|
1992
|
0.77
|
|
33
|
CD38 modifications in chronic lymphocytic leukemia: are they relevant?
|
Leukemia
|
2004
|
0.77
|
|
34
|
Clinical usefulness of peripheral blood lymphocyte subsets in canine lymphoma.
|
Vet Res Commun
|
2003
|
0.77
|
|
35
|
Identification of granulocyte-macrophage colony stimulating factor receptor mRNA by non-isotopic in situ hybridization in bone marrow biopsies.
|
Haematologica
|
1995
|
0.76
|
|
36
|
p53 expression and proliferative activity predict survival in non-invasive thymomas.
|
Int J Cancer
|
1996
|
0.76
|
|
37
|
Biological heterogeneity of diffuse mixed small and large cell non-Hodgkin's lymphomas assessed by DNA flow cytometry and Ki67.
|
Leuk Lymphoma
|
1995
|
0.75
|
|
38
|
Comparison of clinical, morphological, immunophenotypical and cytochemical characteristics of LGL leukemia/lymphoma in dog, cat and human.
|
Eur J Histochem
|
1997
|
0.75
|
|
39
|
CD5-positive B-cells of the fetal and adult spleen lymphoid tissue: an immunophenotypical study.
|
Verh Dtsch Ges Pathol
|
1990
|
0.75
|
|
40
|
CD56-positive cutaneous lymphoma: a poorly recognized entity in the spectrum of primary cutaneous disease.
|
Br J Dermatol
|
1997
|
0.75
|
|
41
|
Heterogeneous immunoglobulin gene rearrangement in a B-chronic lymphocytic leukemia progressing into non-Hodgkin lymphoma (Richter syndrome).
|
Cancer
|
1993
|
0.75
|
|
42
|
Effect of human interleukin 3 on the susceptibility of fresh leukemia cells to interleukin-2-induced lymphokine activated killing activity.
|
Leukemia
|
1992
|
0.75
|
|
43
|
A case-control study on lymphocytic subsets in elderly bearing a gastroenteric cancer.
|
Panminerva Med
|
1997
|
0.75
|
|
44
|
Systemic high-dose recombinant-alpha-2a-interferon therapy modulates lymphokine production in multiple sclerosis.
|
J Neurol Sci
|
1996
|
0.75
|
|
45
|
Cell proliferation, bcl-2, c-myc, p53 and apoptosis as indicators of different aggressiveness in small lymphocytic lymphoma (SLL).
|
Eur J Haematol
|
1997
|
0.75
|
|
46
|
Infiltrating leukocyte populations and T-lymphocyte subsets in head and neck squamous cell carcinomas from patients receiving perilymphatic injections of recombinant interleukin 2. A pathologic and immunophenotypic study.
|
Mod Pathol
|
1990
|
0.75
|
|
47
|
An immunoenzyme technique for the identification of granulocyte-macrophage colony-stimulating factor (GM-CSF) receptors using digoxigenated-GM-CSF.
|
J Immunol Methods
|
1993
|
0.75
|
|
48
|
B-cell chronic lymphocytic leukaemia stage 0. An immunophenotypic study of 66 cases and comparison with B small cell lymphomas.
|
Eur J Haematol
|
1994
|
0.75
|
|
49
|
Relationship between structure and T-lymphocyte maturation in human thymomas. Enzyme histochemical and immunohistological studies.
|
Virchows Arch B Cell Pathol Incl Mol Pathol
|
1987
|
0.75
|
|
50
|
Cancer cells in effusions and increases in T-activated lymphocytes.
|
Eur J Cancer
|
1990
|
0.75
|
|
51
|
Isochromosome 6p and deletion of 6q characterize two related cytogenetic clones in a patient with immunoblastic lymphoma.
|
Cancer Genet Cytogenet
|
1995
|
0.75
|